small molecule

JADENU

DEFERASIROX

Loss of exclusivityNovember 2034latest FDA-listed patent expiry
CompanyNovartisView the full company profile on CliffBio

Drug detail

Brand nameJADENU
Active ingredientDEFERASIROX
Strength90MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2015
Marketing statusRX

Listed patents

PatentExpiresType
9283209November 2034substance, product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Not found